A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis

American Journal of Ophthalmology

Volumn 123, Issue 4, 1997, Pages 455-464

  Friedlaender, M H ^a   Howes, J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LOTEPREDNOL ETABONATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOCULAR FOREIGN BODY; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PAPILLARY CONJUNCTIVITIS; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030999849     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(14)70171-0     Document Type: Article

References (17)

1. Allansmith MR Korb DR Greiner JV Henriquez AS Simon MA Finnemore VM Giant papillary conjunctivitis in contact lens wearers Am J Ophthalmol 83 1977 697 708
2. Allansmith MR Ross RN Ocular allergy and mast cell stabilizers Surv Ophthalmol 30 1986 229 244
3. Donshik PC Ballow M Luistro A Samartino L Treatment of contact lens-induced giant papillary conjunctivitis CLAO J 10 1984 346 350
4. Wood TS Stewart RH Bowman RW McCulley JP Reaves TA Jr Suprofen treatment of contact lens-associated giant papillary conjunctivitis Ophthalmology 95 1988 822 826
5. Bodor N Soft drugs: principles and methods for the design of safe drugs Med Res Rev 4 1984 449 469
6. Bodor N Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems In: Advances in Drug Research 13 1984 255 331
7. Druzgala P Wu WM Bodor N Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes Curr Eye Res 10 1991 933 937
8. Bartlett JD Horwitz B Laibovitz R Howes JF Intraocular pressure response to loteprednol etabonate in known steroid responders J Ocul Pharmacol 9 1993 157 165
9. Bartlett JD Howes JF Ghormley NR Amos JF Laibovitz R Horwitz B Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis Curr Eye Res 12 1993 312 321
10. Newcombe RG Duff GR Eyes or patients? Traps for the unwary in the statistical analysis of ophthalmological studies Br J Ophthalmol 71 1987 645 646
11. Ederer F Refereeing clinical research papers for statistical content Am J Ophthalmol 100 1985 735 737
12. Cochran WG Some methods for strengthening the common chi-square test Biometrics 10 1954 417 451
13. Stewart RH Smith JP Rosenthal AL Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate Curr Eye Res 3 1984 835 839
14. Armaly MF Statistical attributes of the steroid hypertensive response in the clinically normal eye, I: the demonstration of three levels of response Invest Ophthalmol 4 1965 187 197
15. Becker B Intraocular pressure response to topical corticosteroids Invest Ophthalmol 4 1965 198 205
16. Mindel JS Tavitian HO Smith H Walker EC Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate Arch Ophthalmol 98 1980 1577 1578
17. Yablonski ME Burde RM Kolker AE Becker B Cataracts induced by topical dexamethasone in diabetics Arch Ophthalmol 96 1978 474 476